Related Experiment Video

Updated: Apr 29, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

9.1K

Remission of disseminated cancer after systemic oncolytic virotherapy

Stephen J Russell1, Mark J Federspiel2, Kah-Whye Peng2

  • 1Department of Molecular Medicine, Mayo Clinic, Rochester, MN; Division of Hematology, Mayo Clinic, Rochester, MN.

Mayo Clinic Proceedings
|May 20, 2014
PubMed

Insights

Engineered measles virus (MV-NIS) shows promise in treating drug-refractory myeloma by selectively destroying cancer cells. Patients experienced tumor reduction and one achieved durable remission, with therapy monitored by radioiodine imaging.

Area of Science:

  • Oncology
  • Virology
  • Immunotherapy

Background:

  • Multiple myeloma is a cancer of plasma cells.
  • Relapsed or refractory myeloma presents significant treatment challenges.
  • Oncolytic viruses are being explored as targeted cancer therapies.

Observation:

  • Two patients with relapsing, drug-refractory myeloma and plasmacytomas received MV-NIS therapy.
  • MV-NIS is an engineered measles virus designed for myeloma cell destruction.
  • Noninvasive radioiodine imaging monitors NIS gene expression, indicating virus activity.

Findings:

  • Both patients showed positive responses, including reduced M protein and bone marrow plasmacytosis.
  • One patient achieved a durable complete remission across all disease sites.
  • Tumor targeting was confirmed by NIS-mediated radioiodine uptake in plasmacytomas.
  • Observed toxicities were transient and resolved within a week.

Implications:

  • MV-NIS demonstrates potential as a targeted oncolytic virotherapy for multiple myeloma.
  • Radioiodine imaging provides a method for monitoring therapeutic efficacy.
  • Oncolytic viruses represent a promising avenue for treating disseminated cancers.

More Related Videos

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats08:55

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats

Published on: April 15, 2016

8.9K
Ex Vivo Infection of Live Tissue with Oncolytic Viruses12:08

Ex Vivo Infection of Live Tissue with Oncolytic Viruses

Published on: June 25, 2011

13.5K

Related Concept Videos

Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.3K
Cancer Therapies02:49

Cancer Therapies

2.4K
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.1K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
5.2K